If we can see it, we can treat it!
Lu-177 PSMA Treatment for Metastatic Castrate Resistant Prostate Cancer is now available at INITIO!
Lu-177 PSMA treatment, also known as Lutetium-177 PSMA therapy, is a type of targeted radiation therapy that uses a radioactive substance called Lutetium-177 (Lu-177) and a prostate-specific membrane antigen (PSMA) to target and kill cancer cells in the body.
PSMA is a protein that is found on the surface of prostate cancer cells. Lu-177 is a radioactive substance that emits radiation that can penetrate the cancer cell and damage its DNA, leading to cell death. When Lu-177 is attached to PSMA, it can deliver the radiation directly to the cancer cells, while sparing the healthy cells.
The Lu-177 treatment for mCRPC involves injecting the patient with a small amount of radioactive Lu-177 PSMA compound, which is then absorbed by the cancer cells. The radiation emitted by the Lu-177 destroys the cancer cells, while leaving the healthy cells largely unharmed.
The number of doses required varies based on individual response. The average treatment length is 4-5 sessions with a maximum of 6.
Studies have shown that Lu-177 treatment can effectively treat mCRPC that has progressed after standard hormone therapy. In a phase 3 clinical trial, Lu-177 treatment was found to significantly improve overall survival and progression-free survival in patients with mCRPC, compared to standard therapy.
Like any medical treatment, Lu-177 therapy may cause side effects. Commonly reported side effects include:
Most symptoms go away in a few days.
Common and rare but important side effects will be discussed at your consultation with the nuclear medicine physician
Our clinic is welcoming and designed for patient comfort. INITIO was designed for patient comfort and prioritizes patient needs and care. Every INITIO patient will have a private room for the injection and uptake process, in preparation for the scan.
#300 – 3185 Willingdon Green
Burnaby, BC V5G 4P3
Hours of operation: Monday to Friday 9AM-5PM